**Chlamydia trachomatis** antigens in enteroendocrine cells and macrophages of the small bowel in patients with severe irritable bowel syndrome

Aldona Dlugosz¹, Hans Törnblom¹, Ghazaleh Mohammadian¹, Gareth Morgan², Béla Veress⁴, Benjamin Edvinsson⁵, Gunnar Sandström³, Greger Lindberg¹*

**Abstract**

**Background:** Inflammation and immune activation have repeatedly been suggested as pathogenic factors in irritable bowel syndrome (IBS). The driving force for immune activation in IBS remains unknown. The aim of our study was to find out if the obligate intracellular pathogen *Chlamydia* could be involved in the pathogenesis of IBS.

**Methods:** We studied 65 patients (61 females) with IBS and 42 (29 females) healthy controls in which IBS had been excluded. Full thickness biopsies from the jejunum and mucosa biopsies from the duodenum and the jejunum were stained with a monoclonal antibody to *Chlamydia* lipopolysaccharide (LPS) and species-specific monoclonal antibodies to *C. trachomatis* and *C. pneumoniae*. We used polyclonal antibodies to chromogranin A, CD68, CD11c, and CD117 to identify enteroendocrine cells, macrophages, dendritic, and mast cells, respectively.

**Results:** *Chlamydia* LPS was present in 89% of patients with IBS, but in only 14% of healthy controls (p < 0.001) and 79% of LPS-positive biopsies were also positive for *C. trachomatis* major outer membrane protein (MOMP). Staining for *C. pneumoniae* was negative in both patients and controls. *Chlamydia* LPS was detected in enteroendocrine cells of the mucosa in 90% of positive biopsies and in subepithelial macrophages in 69% of biopsies. Biopsies taken at different time points in 19 patients revealed persistence of *Chlamydia* LPS up to 11 years. The odds ratio for the association of *Chlamydia* LPS with presence of IBS (43.1; 95% CI: 13.2-140.7) is much higher than any previously described pathogenetic marker in IBS.

**Conclusions:** We found *C. trachomatis* antigens in enteroendocrine cells and macrophages in the small bowel mucosa of patients with IBS. Further studies are required to clarify if the presence of such antigens has a role in the pathogenesis of IBS.

**Background**

The irritable bowel syndrome (IBS) is a common disorder that may affect as many as 9%-15% of the population in Western countries [1-3]. IBS is characterized by abdominal pain and disturbed bowel function in the absence of a detectable organic disease, which may explain the symptoms [4]. The presence of disturbed gut function in IBS may indicate an underlying pathology in control systems or effectors of the gut. We have previously reported lymphocytic infiltration and neuron damage in myenteric ganglia when full-thickness biopsies from the jejunum in 10 patients with severe IBS were investigated [5], and there are many reports that have highlighted signs of an activated immune system as a putative pathogenetic mechanism in IBS (for review see de Giorgio [6]). However, the aetiology of observed immune activation remains unsolved.
Studies have repeatedly indicated that IBS can arise after an acute gastroenteritis. The underlying mechanism of post-infectious IBS has not been established but ongoing inflammation appears to play a role, with an increase in enteroeendocrine cells, lymphocytes, mast cells, and proinflammatory cytokines (for review, see Spiller[7]). However, in a recent study of ours the actual agent causing gastroenteritis was not a predictor of risk for IBS [8]. Consequently, a host factor, such as a pre-existing chronic infection with a different microbe than the agent causing gastroenteritis, might explain the development of IBS. We presumed that a candidate agent should be compatible with an asymptomatic carrier-ship, have a preference for female gender, and have the ability to become persistent and to live in bowel epithelium. There are some observations to support the idea that a persistent infection with Chlamydia trachomatis might constitute such a host factor. Trachoma-related blindness is 2-4 times more likely to affect females compared to males [9]. It is known that IBS occurs in 35%-50% of females with chronic pelvic pain syndrome, which is believed to often be caused by chronic infection with C. trachomatis [10-12]. A previous attempt to link C. trachomatis to IBS using serum IgG antibodies failed [13], but IgG antibody patterns may be insufficient to rule out persistence of Chlamydia due a dominating cellular immune response to infection [14,15]. Since we had previously found inflammation in mucosa and enteric ganglia of the jejunum in patients with IBS we decided to reanalyze archived biopsy material to find out if Chlamydia antigens are present in the small bowel in this group of patients.

Methods

Patients

All patients fulfilled Rome-II criteria for IBS [4]. A total of 65 patients (61 females and 4 males) with a median age of 48 (range 22-67) years and a median duration of IBS symptoms of 6.5 years (range 0.6-33.2 years) were investigated. Diarrhoea predominant IBS was present in 21 patients (32%), 22 patients (34%) had constipation predominant IBS and 22 patients (34%) had IBS with alternating bowel habits. All patients had severe symptoms of IBS [5] and 26 patients also exhibited abnormalities on small bowel manometry, thus qualifying for a pathophysiological diagnosis of enteric dysmotility [16]. Full thickness jejunal biopsies had been taken in 60 of our patients. Previous histopathological analysis had revealed neuropathic changes in 58 patients [5,17,18]. Neuropathy was associated with low-grade inflammation (LG = lymphocytic ganglionitis) in 46 patients and 20 of these also exhibited increased numbers of intraepithelial lymphocytes (LEG = lymphocytic epithelio-ganglionitis), whereas 12 patients had degenerative neuropathy (DN) without inflammation. Deficient staining for alpha-actin without neuronal damage was observed in 2 patients.

Controls

The control group comprised 42 persons (29 females) in whom IBS and all other functional bowel disorders had been excluded by medical interview and a validated questionnaire for the Rome-II symptom criteria. Ten controls (7 females) were obese but otherwise healthy (BMI mean = 42.8, SD = 4.3). The rest of the control group (32 persons, 22 females) consisted of healthy volunteers. The median age of the controls was 36 (range 19-60) years.

Full thickness jejunal biopsy

Previously obtained full-thickness biopsy specimens were available in 60/65 patients. The biopsies had been taken from the proximal jejunum using a laparoscopy-assisted procedure described by Tornblom et al[5] Ten obese controls underwent full thickness biopsy of the jejunum at the time of gastric by-pass surgery.

Mucosa biopsy

Mucosa specimens from the proximal jejunum were taken with a Watson capsule in 32 controls and 6 patients. The capsule was swallowed by the subject and brought by peristalsis to a position distal to the ligament of Treitz as determined by fluoroscopy. We analyzed archived endoscopic mucosa biopsies from the duodenum of 20 patients and in 15 of these full thickness biopsies were also available. In 2 patients we analyzed mucosa biopsies from both the jejunum and the duodenum.

Immunofluorescence

Immunofluorescence was performed using a genus-specific mouse monoclonal antibody to Chlamydia lipopolysaccharide (LPS)-FITC conjugated with Evans blue (RDI-PROAC1FT, Fitzgerald Industries International, Concord, MA, USA) and C. trachomatis major outer membrane protein (MOMP) as primary antibody (GeneTex, San Antonio, TX, USA) and C. trachomatis major outer membrane protein (MOMP) as primary antibody (GeneTex, San Antonio, TX, USA) and a polyclonal rabbit anti-mouse antibody-FITC conjugated (Dako, Glostrup, Denmark) as the secondary antibody. We used cultured HeLa-cells infected with C. trachomatis as positive control and uninfected cells as negative control. We used a species-specific mouse monoclonal antibody for C. pneumoniae as primary antibody (GeneTex, San Antonio, TX, USA) with a polyclonal rabbit anti-mouse antibody-FITC conjugated (Dako, Glostrup, Denmark) as the secondary antibody. The presence of Chlamydia LPS was also evaluated using immunohistochemistry with a polyclonal rabbit antibody to C. trachomatis LPS (Fitzgerald Industries International, Concord, MA) and
an immunoenzymatic assay with Streptavidin-biotin complex (Dako, Glostrup, Denmark).

Enterocyte cells were identified using rabbit polyclonal antibodies to Chromogranin A (Abcam, Cambridge, UK), and we used rabbit polyclonal antibodies to CD117 (Dako, Glostrup, Denmark) for mast cells, rabbit polyclonal antibodies to CD68 (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for macrophages and rabbit monoclonal antibodies to CD11c (Abcam, Cambridge, UK) for dendritic cells. Goat anti-rabbit antibodies conjugated with Alexa Fluor 568 or Alexa Fluor 350 (Invitrogen, Carlsbad, CA, USA) were used as secondary antibody for all of the rabbit antibodies.

Stained sections were examined using a Universal Laser Scanning Confocal Microscope System Leica TCS and a Fluorescent Microscope System Leica DMRXA (Leica Microsystems, Wetzlar, Germany). Two independent investigators (AD and GM), who were unaware of clinical data, made the final assessment of slides. The slides were reviewed by a third investigator (BV). The immunofluorescence stainings were considered positive if more than one cell showed fluorescence. If only one positive cell was found, the staining-procedure was repeated. The case was regarded positive if the colour signal was again present, otherwise the case was recorded as negative. Double immunofluorescence stainings were also performed for the identification of LPS-positive cells (LPS with chromogranin, CD68, CD117, or CD11c, respectively).

Western blotting

Snap-frozen biopsies from 4 patients that were positive for Chlamydia LPS staining, were examined by Western blotting. HeLa cells infected with C. trachomatis served as positive control and we used non-infected HeLa cells as negative control. Equivalent amounts of protein from each specimen were loaded onto a sodium dodecyl sulphate-polyacrylamide gel. After electrophoresis, samples were transferred to nitrocellulose membranes. We used a mouse monoclonal antibody to C. trachomatis LPS (AbD Serotec, Oxford, UK) as primary antibody and goat anti-mouse antibody conjugated to horseradish peroxidase (BioRad, Hercules, CA, USA) as secondary antibody. For MOMP we used the same primary antibody as for immunofluorescence.

MicroLaser system

We used Laser Microdissection Pressure Catapulting (LMPC) for laser based non-contact extraction of tissue areas in paraffin embedded biopsies from 6 patients. Regions of interest were manually delineated using fluorescence microscopy and the LMPC software. Tissue collection was achieved by laser cutting along the delineation lines to separate tissue of interest from surrounding regions, and secondly the laser catapulted the tissue of interest up into the lid of an Eppendorf cap containing sterile water. DNA was extracted using a QiaAmp DNA mini kit, according to the instructions of the manufacturer, and analyzed by PCR.

Real-time PCR

In the present study, we used the real-time PCR assay developed by Everett et al. [19], which amplifies 23S ribosomal DNA, and detects all members of the family Chlamydiaceae. An internal amplification control was included to monitor possible inhibition of the PCR. DNA from frozen biopsies, taken from 4 patients previously positive for Chlamydia LPS staining, was extracted using a Qiagen minikit according to the tissue protocol (Qiagen, Solna, Sweden). Extracted DNA was quantified and quality controlled using a Nanodrop spectrophotometer (Nanodrop Technologies, Wilmington, DE, USA) before being subjected to PCR.

Transmission electron microscopy

Biopsies from the distal duodenum of 4 patients that were positive for Chlamydia LPS staining were fixed according to a procedure described before [20]. Semithin sections were cut and stained with toluidin blue and used for light microscopic analysis. Ultra-thin sections were contrasted with uranyl acetate followed by lead citrate and examined in a Tecnai 10 transmission electron microscope at 80 kV. Digital images were taken by using a MegaView III digital camera (Soft Imaging System, Münster, Germany).

Statistical analysis

We used logistic regression with age and gender as covariates for calculation of odds ratios and p-values for comparisons of proportions. The size of the study group was determined from the assumption that LPS positivity would be no greater than 20% among controls. In order to detect a risk factor with an odds ratio of at least 6 at p < 0.01 with power >90% we needed to include at least 37 patients and 37 controls (two-sided test).

Ethical considerations

All parts of the study were approved by the Regional Ethical Review Board in Stockholm. Informed consent was obtained from all patients and controls at the time of biopsy taking.

Results

Immunofluorescence (IF) staining showed that 53/60 patients were positive for Chlamydia LPS in full thickness jejunum biopsies. Positive staining occurred in a few cells both within the epithelium and in lamina propria (Figure 1). No Chlamydia LPS-positive cells were
found in the submucosa and muscularis propria or the enteric nervous system. Since we had full thickness biopsies from only 10 controls, we investigated if the finding of LPS-positive cells could be reproduced in biopsies from small bowel mucosa. We investigated mucosal biopsies from 24 of our patients with IBS and 32 controls. Staining of slides from these biopsies yielded similar rates of positive stainings: 21/24 (88%) patients were positive for *Chlamydia* LPS again in a few cells within the epithelium and in l. propria. In 19 patients biopsies had been taken with a time interval of more than 1 year. *Chlamydia* LPS was present in biopsies with a median time difference of 5.2 (range 1-11) years. Overall, 58/65 (89%) patients were classified as *Chlamydia* LPS positive. Six women and one man with IBS were negative in all biopsies.

In 90% of positive biopsies from patients *Chlamydia* LPS was localised to mucosal cells at the level of the crypts. Double staining with antibodies to chromogranin-A showed that *Chlamydia* LPS was present in mucosal cells at the level of the crypts. Double staining with antibodies to chromogranin-A showed that *Chlamydia* LPS was present in mucosal cells at the level of the crypts. Double staining with antibodies to chromogranin-A showed that *Chlamydia* LPS was present in mucosal cells at the level of the crypts. Double staining with antibodies to chromogranin-A showed that *Chlamydia* LPS was present in mucosal cells at the level of the crypts. Double staining with antibodies to chromogranin-A showed that *Chlamydia* LPS was present in mucosal cells at the level of the crypts. Double staining with antibodies to chromogranin-A showed that *Chlamydia* LPS was present in mucosal cells at the level of the crypts. Double staining with antibodies to chromogranin-A showed that *Chlamydia* LPS was present in mucosal cells at the level of the crypts. Double staining with antibodies to chromogranin-A showed that *Chlamydia* LPS was present in mucosal cells at the level of the crypts. Double staining with antibodies to chromogranin-A showed that *Chlamydia* LPS was present in mucosal cells at the level of the crypts. Double staining with antibodies to chromogranin-A showed that *Chlamydia* LPS was present in mucosal cells at the level of the crypts. Double staining with antibodies to chromogranin-A showed that *Chlamydia* LPS was present in mucosal cells at the level of the crypts. Double staining with antibodies to chromogranin-A showed that *Chlamydia* LPS was present in mucosal cells at the level of the crypts. Double staining with antibodies to chromogranin-A showed that *Chlamydia* LPS was present in mucosal cells at the level of the crypts. Double staining with antibodies to chromogranin-A showed that *Chlamydia* LPS was present in mucosal cells at the level of the crypts. Double staining with antibodies to chromogranin-A showed that *Chlamydia* LPS was present in mucosal cells at the level of the crypts. Double staining with antibodies to chromogranin-A showed that *Chlamydia* LPS was present in mucosal cells at the level of the crypts. Double staining with antibodies to chromogranin-A showed that *Chlamydia* LPS was present in mucosal cells at the level of the crypts. Double staining with antibodies to chromogranin-A showed that *Chlamydia* LPS was present in mucosal cells at the level of the crypts. Double staining with antibodies to chromogranin-A showed that *Chlamydia* LPS was present in mucosal cells at the level of the crypts. Double staining with antibodies to chromogranin-A showed that *Chlamydia* LPS was present in mucosal cells at the level of the crypts. Double staining with antibodies to chromogranin-A showed that *Chlamydia* LPS was present in mucosal cells at the level of the crypts. Double staining with antibodies to chromogranin-A showed that *Chlamydia* LPS was present in mucosal cells at the level of the crypts. Double staining with antibodies to chromogranin-A showed that *Chlamydia* LPS was present in mucosal cells at the level of the crypts. Double staining with antibodies to chromogranin-A showed that *Chlamydia* LPS was present in mucosal cells at the level of the crypts. Double staining with antibodies to chromogranin-A showed that *Chlamydia* LPS was present in mucosal cells at the level of the crypts. Double staining with antibodies to chromogranin-A showed that *Chlamydia* LPS was present in mucosal cells at the level of the crypts. Double staining with antibodies to chromogranin-A showed that *Chlamydia* LPS was present in mucosal cells at the level of the crypts. Double staining with antibodies to chromogranin-A showed that *Chlamydia* LPS was present in mucosal cells at the level of the crypts.
enteroendocrine cells within the epithelium (Figure 1). Chlamydia LPS was found in l. propria cells in 69% of the biopsies from patients. Double staining with antibodies to CD117, CD11c and CD68 revealed that in this location Chlamydia LPS was present in macrophages. Seventy-nine percent of Chlamydia LPS positive biopsies were also positive to C. trachomatis MOMP (Figure 1). Staining for C. pneumoniae was negative in all patients.

Only 6/42 (14%) controls (5 women) were positive for Chlamydia LPS (6 in l. propria macrophages and 2 in enteroendocrine cells) and 2/6 LPS-positive controls were positive to C. trachomatis MOMP. No biopsies from controls were positive for C. pneumoniae. Slides from 10 patients who were positive for Chlamydia LPS in immunofluorescence and 10 negative controls were studied using immunohistochemistry with polyclonal antibodies to Chlamydia LPS and streptavidin-biotin complex. Chlamydia LPS was found in enteroendocrine cells and/or macrophages in all cases whereas all controls remained negative.

The prevalence of Chlamydia LPS was much higher in patients with IBS (58/65) than it was among controls (6/42). The odds ratio, corrected for differences in age and gender distributions, for mucosal Chlamydia LPS being indicative for presence of IBS was 43.1 (95% CI: 13.2-140.7). Biopsies were analysed by two independent investigators unaware of clinical data. The agreement between the two investigators regarding individual biopsies was 94%, whereas their agreement regarding patient classification was 100%.

We found no correlation between presence of Chlamydia antigens and the type of neuropathy in patients with full thickness biopsies. Although the majority of patients had neuropathy with inflammation, Chlamydia antigens were common also among those who had neuropathic changes without inflammation (LEG: 19/20 = 95%; LG 23/26 = 88%; DN 9/12 = 75%). We found no difference between IBS subgroups with regard to positivity for Chlamydia antigens and 19/21 with D-IBS, 22/22 with C-IBS, and 17/22 with A-IBS were LPS positive.

New biopsies were taken from the duodenum mucosa in 4 LPS-positive patients (Table 1). We confirmed the presence of Chlamydia LPS antigen in patients with Western blotting but the new biopsies were negative for C. trachomatis MOMP both in immunofluorescence and Western blot (Figure 2). Electron microscopy revealed small oval structures resembling intermediate bodies of Chlamydia with characteristic condensed nucleoids of nucleic acid (Figure 3). Mitochondria were observed surrounding the inclusions but did not appear to be in close association with the inclusions. We were unable to confirm the presence of Chlamydia DNA in the same biopsies using 23S ribosomal DNA as target. Results were negative for Chlamydia DNA also when we analyzed micro-dissected Chlamydia LPS positive cells.

### Discussion

We report the novel finding of chlamydial antigens in enteroendocrine cells and macrophages of the small bowel mucosa in patients with severe IBS. LPS and MOMP antigens were detected in mucosa and l. propria of the small bowel in a large majority of patients with IBS, but rarely so in healthy controls. The odds ratio for mucosal Chlamydia LPS being indicative for presence of IBS is much higher than any previously described

---

**Table 1 Onset of disease and results from immunofluorescence staining for Chlamydia LPS and C. trachomatis MOMP, Western blot, polymerase chain reaction (PCR), and electron microscopy (EM) in 4 patients selected for new biopsies**

| Patient | Onset of IBS symptoms | Archive biopsies | New biopsies 2007 | Western blot 2007 | PCR | EM |
|---------|-----------------------|------------------|-------------------|------------------|-----|----|
|         |                       | Year | LPS | MOMP | LPS | MOMP | LPS | MOMP | Year | LPS | MOMP | LPS | MOMP |
| 1       | 1994                  | 1996 | +   | +    | +   | -    | -   | -    | 2007 | +   | +    | +   | +    |
| 2       | 1985                  | 2000 | +   | +    | -   | -    | -   | -    | 2007 | +   | +    | +   | +    |
| 3       | 1968                  | 2001 | +   | +    | +   | -    | -   | -    | 2007 | +   | +    | +   | +    |
| 4       | 1977                  | 1997 | +   | +    | +   | -    | -   | -    | 2007 | +   | +    | +   | +    |

**Figure 2 Western blot.** Western blot analysis of small bowel biopsies from 4 IBS patients against mouse immune sera to LPS and MOMP, respectively. 1-4 = IBS patients, ++ = HeLa cells infected with C. trachomatis (10 μl), + = HeLa cells infected with C. trachomatis (5 μl), - = non-infected HeLa cells.
pathogenetic marker in IBS [21]. These findings raise several questions. The first is whether or not observed immunofluorescence findings represent presence of bacterial antigens. The specificity of the LPS antibody is important in this respect. There is a risk that antibodies may give rise to unspecific binding but such binding should not differ between patients and controls. We therefore think that unspecific binding is an unlikely explanation for our findings. It has previously been shown that this monoclonal anti-LPS antibody does not bind to environmental Chlamydiae [22,23]. The genus-specific LPS epitope is not shared by other known gram-negative bacteria and monoclonal antibodies do not bind LPS of those organisms [24]. Thus, positive staining of LPS can be considered as a marker of past or present Chlamydia infection. We used different techniques to visualize Chlamydia LPS. In addition to immunofluorescence with a FITC-conjugated monoclonal antibody, we used a polyclonal antibody to Chlamydia LPS and the standard streptavidin-biotin technique for light microscopy. The latter technique also showed presence of antigen in the same cell types. We used Western blot on new biopsies from a limited number of patients and confirmed that Chlamydia LPS was present in the tissue samples from these patients. These findings further support the hypothesis that observed antigens have a bacterial origin.

The second question concerns the identity of the species involved. We used a genus-specific antibody to Chlamydia LPS and species-specific antibodies to C. pneumoniae and C. trachomatis MOMP. Since we found positive staining for C. trachomatis MOMP in 79% of Chlamydia LPS biopsies and none of them was positive for C. pneumoniae we hypothesized that the origin of these antigens is a past or present infection with C. trachomatis.

The third question is if observed antigens represent an ongoing infection or not. We investigated archived biopsy material from the small bowel and this puts certain limits on our ability to ascertain the underlying cause for observed findings as well as their specificity. To confirm and strengthen our immunohistochemical findings we used antibodies to different antigens and also different methods of visualisation. In a limited number of cases we had the opportunity to take new biopsies for more advanced analyses using molecular biology techniques, proteomics and electron microscopy. Whereas electron microscopy showed presence of Chlamydia-like organisms in the cytoplasm of enteroendocrine cells, similar to those described in persistent C. trachomatis infection [25], we were unable to detect chlamydial DNA in a small number of patients using standard extraction and amplification protocols. It is possible that the standard methods we used for nucleic
motility disorders could be excluded. Severe IBS to healthy controls in which IBS and other diseases to rule out the co-existence of IBS with such diseases and this might blur the results of such a comparison. We therefore decided to compare our patients with severe IBS and other gastrointestinal diseases is unknown. [35]. The specificity of Chlamydia antigens for IBS cannot determine if patients with severe IBS have an ongoing intestinal infection with C. trachomatis or not. Neither can we explain the presence of inflammation in myenteric ganglia or neuropathy by the finding of Chlamydia antigens in enteroendocrine cells. A possible link between the presence of Chlamydia antigens in enteric cells and myenteric inflammation could be autoimmune mechanisms related to heat shock protein 60 [29], but at this time such a mechanism remains purely speculative.

We found Chlamydia antigen also in macrophages. It is known that Chlamydiae become spontaneously persistent following the infection of monocytes and the monocyte is the common host cell for Chlamydiae during persistent infection [30-32]. Chlamydiae may participate in the maintenance of local immunological response and inflammation via infected monocytes/macrophages and also use them to spread infection to other organs [33].

Some of our Chlamydia LPS positive patients did not show the presence of MOMP antigen. Chlamydiae down-regulate the major outer membrane protein (MOMP) expression in the persistent state [34]. Attenuated synthesis of MOMP, usually considered the immuno-dominant surface epitope of the organism, in combination with its almost exclusively intracellular location during persistence may help to provide some relative invisibility from immune surveillance [34].

The presence of C. trachomatis antigens in small bowel mucosa has not been demonstrated in IBS patients before. However, it is known that Chlamydiae can persist in the intestinal mucosa of certain animals for a long time without infection-induced inflammation [35]. The specificity of C. trachomatis antigens for IBS compared to other gastrointestinal diseases is unknown. We did not have access to biopsies from the upper small intestine of patients with for example Crohn’s disease or ulcerative colitis. At the same time, it is difficult to rule out the co-existence of IBS with such diseases and this might blur the results of such a comparison. We therefore decided to compare our patients with severe IBS to healthy controls in which IBS and other motility disorders could be excluded.

The finding of C. trachomatis antigens in enteroendocrine cells makes it tempting to suggest a novel pathogenetic mechanism in IBS. Enteroendocrine cells play a pivotal role in the control of gut motility and secretion and increased numbers of enteroendocrine cells have been detected in patients that developed IBS after an acute gastroenteritis [36]. It is unknown if infection alters the function of enteroendocrine cells in man but animal experiments using different models of enteric infection have shown pronounced changes in both numbers of enteroendocrine cells and their function [37,38]. Serotonin-producing enteroendocrine cells may present an ideal location for Chlamydia due to their abundance of tryptophan. Tryptophan is required for normal development in Chlamydia species and tryptophan metabolism has been implicated in Chlamydia persistence and tissue tropism [39]. We hypothesize that Chlamydia actively may enter EEC searching for tryptophan. Infection may impair EEC serotonin and hormone secretion and cause motility disturbances but further studies on enteroendocrine cell lines or cultured EEC are required for elucidating such a mechanism.

Conclusions
We found chlamydial antigens in enteroendocrine cells and macrophages of the small bowel mucosa in 89% of patients with IBS but in only 14% of controls. Even though we were unable to prove the presence of viable Chlamydia, lack of positive PCR being the major obstacle, the evidence for an intracellular organism or at least a protein structure with an antigen in common with Chlamydia in patients with IBS is strong. Our results suggest that the presence of C. trachomatis antigens in enteroendocrine cells may be involved in the pathogenesis in IBS.

Abbreviations
CI: confidence interval; DN: degenerative neuropathy; DNA: deoxyribonucleic acid; EEC: enteroendocrine cells; FITC: fluorescein (-isothiocyanate); IBS: irritable bowel syndrome; LEG: lymphocytic epithelio-ganglionitis; LG: lymphocytic ganglionitis; LPS: lipopolysaccharide; LMPC: laser microdissection pressure catapulting; MOMP: major outer membrane protein; PCR: polymerase chain reaction.

Acknowledgements
This study was supported by grants from the Stockholm County Council and Karolinska Institutet Regional Project Funding (ALF grants 2005-0339 and 2006-0357), The Swedish Society of Medicine (The Bengt Ihre foundation), and Foundation Olle Engkvist Byggmästare. AD is the recipient of a Rome Foundation Fellowship in Functional GI and Motility Disorders. None of the funding sources had any involvement with the study. We are grateful to Kjell Hulténby for excellent electron microscopy work.

Author details
1Department of Medicine, Division of Gastroenterology and Hepatology, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden. 2Department of Laboratory Medicine, Division of Pathology, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden. 3Department of Laboratory Medicine, Division of Microbiology, Karolinska Institutet, Karolinska University Hospital, Huddinge, Stockholm, Sweden. 4Department of Pathology and Cytology, Lund University, University
Hospital MAS, Malmö, Sweden. 2Centre for Microbiological Preparedness, Swedish Institute for Infectious Disease Control, Solna, Sweden.

Authors’ contributions
AD participated in the design and coordination of the study, carried out the immunohistochemical analyses, performed literature review, and drafted the manuscript. HT participated in collecting clinical data and biopsies from patients. GM obtained clinical data and biopsies from healthy controls. GM participated in the analysis of immunohistochemical stainings. Bv performed the histopathological analysis of full thickness bowel biopsies and reviewed immunohistochemical stainings. BE carried out nucleic acid amplification analyses and Western blot. GS participated in the design of the study and the analysis of data. GL collected clinical data and biopsies from patients, performed the statistical analysis, participated in the design of the study and supervised the study. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 10 August 2009
Accepted: 16 February 2010
Published: 16 February 2010

References
1. Drossman DA, Li Z, Andruzzi E, Temple RD, Talley NJ, Thompson WG, Whitehead WE, Janssens J, Funch-Jensen P, Carozza E, Richter JE, Koch GG. H.S. householder survey of functional gastrointestinal disorders. Prevalence, sociodemography, and health impact. Dig Dis Sci 1993, 38:1569-1580.

2. Ageles L, Svardudd K, Nyren O, Tibblin G. The epidemiology of abdominal symptoms: prevalence and demographic characteristics in a Swedish adult population. A report from the Abdominal Symptom Study. Scand J Gastroenterol 1994, 29:102-109.

3. Meirin F, Badia X, Balboa A, Baro E, Caldwell E, Cucala M, Diaz-Rubio M, Ferrer J, Fernandez-Vinas J, Fiter JM, Garcia-Conde J, Gurniak C, Jimenez-Paz D, Jimenez-Sanchez J, Koeber F, Lamas M, Lazaro J, Longo M, Muntane A, Okada H, Ortega-Ureña M, Palacios J, Pajares A, Papageorgiou A, Pazos R, Perez-San-Martin R, Pons J, Ricart F, Rosell-Jimenez A, Samitier M, Sanchez-Cabo A, Sencadas V, Serrano E, Soler E, Stanek E, Tjioe I, Valkenburg S, Valls O, Villacampa J, Vidal J, Vila M, Vives A, Viñals J, Vivas J, Wahlund M, Zegarra J, Zuidema G. The Rome II criteria for functional bowel disorders and functional abdominal pain. Gut 1999, 45(Suppl 3):i43-47.

5. Tombi I, Lindberg G, Nyberg B, Veress B. Full-thickness biopsy of the jejunum reveals inflammation and enteric neuropathy in irritable bowel syndrome. Gastroenterology 2002, 123:1972-1979.

6. De Giorgi R, Barbara G. Is irritable bowel syndrome an inflammatory disorder?. Curr Gastroenterol Rep 2008, 10:385-390.

7. Spiller RC. Postinfectious irritable bowel syndrome. Gastroenterology 2003, 124:1662-1671.

8. Tombi I, Holmivall P, Svenungsson B, Lindberg G. Gastrointestinal symptoms after infectious diarrhea: a five-year follow-up in a Swedish cohort of adults. Clin Gastroenterol Hepatol 2007, 5:461-464.

9. Courtright P, West SK. Contribution of sex-linked biology and gender roles to disparities with trichoma. Emerg Infect Dis 2004, 10:2012-2016.

10. Prior A, Wilson K, Whorwell PJ, Faragher EB. Irritable bowel syndrome in the gynecologic clinic. Survey of 798 new referrals. Dig Dis Sci 1989, 34:1820-1824.

11. Zondervan KT, Yudkin PL, Vessey MP, Jenkinson CP, Dawes MG, Barlow DH, Zondervan KT, Yudkin PL, Vessey MP, Jenkinson CP, Dawes MG, Barlow DH, Dhillon BV, Hill MB, Holford TR, Horvath S, Stockton J. Postinfectious irritable bowel syndrome. Gastroenterology 2000, 123:782-789.

12. Williams RE, Hartmann KE, Sandler RS, Miller WC, Savitz LA, Steege JF. Recognition and treatment of irritable bowel syndrome among women with chronic pelvic pain. Am J Obstet Gynecol 2003, 190:761-767.

13. Francis C, Prior A, Whorwell PJ, Morris J. Chlamydia trachomatis infection: is it relevant in irritable bowel syndrome?. Digestion 1998, 59:157-159.

14. Wilkinson NZ, Kingsley GH, Seiper J, Braun J, Ward ME. Lack of correlation between the detection of Chlamydia trachomatis DNA in synovial fluid from patients with a range of rheumatic diseases and the presence of an antichlamydial immune response. Arthritis Rheum 1998, 41:845-854.

15. Wiltink SS. Immunological aspects of genital chlamydia infections. Best Pract Res Clin Obstet Gynaecol 2002, 16:865-874.

16. Wingate D, Hongo M, Kellow J, Lindberg G, Smout A. Disorders of gastrointestinal motility: towards a new classification. J Gastroenterol Hepatol 2002, 17(Suppl)S1-14.

17. Lindberg G, Tombi I, Hazzon M, Nyberg B, Martin J, Veress B. Full thickness biopsy findings in chronic intestinal pseudo-obstruction and enteric dysmotility. Gut 2009, 58:1084-1090.

18. Veress B, Nyberg B, Tombi I, Lindberg G. Intestinal lymphocytic epithelioganglionitis: a unique combination of inflammation in bowel dysmotility: a histopathological and immunohistochemical analysis of 28 cases. Histopathology 2009, 54:539-549.

19. Everett KG, Homung LI, Anderssen AA. Rapid detection of the Chlamydiaceae and other families in the order Chlamydiales: three PCR tests. J Clin Microbiol 1999, 37:575-580.

20. Muschol S, Bailey L, Gylfe A, Sundin C, Hultenby K, Bergstrom S, Elfsson M, Wolf-Watz H, Normark S, Henriques-Normark B. A small-molecule inhibitor of type III secretion inhibits different stages of the infectious cycle of Chlamydia trachomatis. Proc Natl Acad Sci USA 2006, 103:14566-14571.

21. Ohman L, Simren M. New insights into the pathogenesis and pathophysiology of irritable bowel syndrome. Dig Liver Dis 2007, 39:201-215.

22. Friedman MG, Dvoskin B, Kahane S. Infections with the chlamydia-like microorganism Simkania negevensis, a possible emerging pathogen. Microbes infect 2003, 5:1015-1021.

23. Collins RG, Toeneshoff ER, Taylor MW, Fritsche TR, Wagner M, Horn M. ‘Candidatus Protocrylamydia amoebophila’, an endosymbiont of Acanthamoeba spp. Int J Syst Evol Microbiol 2005, 55:1863-1866.

24. Caldwell HD, Hitchcock PJ. Monoclonal antibody against a genus-specific antigen of Chlamydia species: location of the epitope on chlamydial lipopolysaccharide. Infect Immun 1997, 65:3306-3314.

25. Nettelnbreker E, Zeidler H, Bartels H, Dreses-Werringloer U, Daubener W, Holtmann H, Kohler L. Studies of persistent infection by Chlamydia trachomatis serovar K in TPA-differentiated U937 cells and the role of IFN-gamma. J Med Microbiol 1998, 47:141-149.

26. Freise J, Gerard HC, Bunkie T, Whittrum-Hudson JA, Zeidler H, Kohler L, Dreses-Werringloer U. Persistent chlamydial envelope antigens in antibiotic-exposed infected cells trigger neutrophil chemotaxis. J Infect Dis 1999, 179:954-966.

27. Boezy WL, Morrison RP, Byrne GI. Persistent chlamydiae: from cell culture to a paradigm for chlamydial pathogenesis. Microbiol Rev 1994, 58:686-699.

28. Yi Y, Yang X, Brunham RC. Autoimmunity to heat shock protein 60 and antigen-specific production of interleukin-10. Infect Immun 1997, 65:1669-1674.

29. Yog liver formation of Candidatus Protochlamydia amoebophila in fermenter cultures. J Clin Microbiol 2005, 43:1099-1108.

30. Prieto J, Lamiel JL, Rust N, Echavarri E, Molin I, Jaque-Cuesta P, Garcia-Delgado M, et al. Infections with the chlamydia-like microorganism Simkania negevensis. J Infect Dis 1999, 179:254-262.

31. Prieto J, Guinovart J, Parrilla P, et al. Infections with the chlamydia-like microorganism Simkania negevensis. J Infect Dis 1999, 179:254-262.

32. Prieto J, Lamiel JL, Rust N, Echavarri E, Molin I, Jaque-Cuesta P, Garcia-Delgado M, et al. Infections with the chlamydia-like microorganism Simkania negevensis. J Infect Dis 1999, 179:254-262.
38. O’Hara JR, Skinn AC, MacNaughton WK, Sherman PM, Sharkey KA. Consequences of Citrobacter rodentium infection on enteroendocrine cells and the enteric nervous system in the mouse colon. Cell Microbiol 2006, 8:646-660.

39. Akers JC, Tan M. Molecular mechanism of tryptophan-dependent transcriptional regulation in Chlamydia trachomatis. J Bacteriol 2006, 188:4236-4243.

Pre-publication history
The pre-publication history for this paper can be accessed here: http://www.biomedcentral.com/1471-230X/10/19/prepub

doi:10.1186/1471-230X-10-19
Cite this article as: Dlugosz et al.: Chlamydia trachomatis antigens in enteroendocrine cells and macrophages of the small bowel in patients with severe irritable bowel syndrome. BMC Gastroenterology 2010, 10:19.